Description of the medicine: Vitamin D3 (cholecalciferol) - aqueous solution ()
VITAMIN D 3 (cholecalciferol) - an aqueous solution.
Synonym: Colecalciferol, Colecalciferol
Vitamins of group D ergocalciferol and cholecalciferol are fat-soluble substances and are used in the form of oil solutions; they are also part of dragee tablets. Recently, a water-soluble dosage form of cholecalciferol (vitamin D 3 ) has been developed, which is convenient for oral use and highly effective in the prevention and treatment of rickets and other pathological conditions associated with a deficiency in the body of vitamin D.
When taken orally, the drug is rapidly absorbed (5 times faster than oil solutions), creates a high concentration of vitamin D in the body and has a long-lasting effect.
The therapeutic effect of the drug, as well as the action of endogenous vitamins D (ergocalciferol and cholecalciferol), is due to the regulation of calcium and phosphate metabolism. Vitamin D 3 promotes the absorption of calcium and phosphates from the intestine, regulates their participation in bone calcification, and slows down the excretion of calcium and phosphorus ions from the body. The regulatory effect on the metabolism of calcium and phosphorus ions also explains other features of the drug: regulation of nervous excitation processes, muscle tone, blood coagulation, etc. (see Calcium preparations and agents for treating osteoporosis).
Apply vitamin D 3 (cholecalciferol) - an aqueous solution with the following indications: prevention and treatment of rickets; hypocalcemic tetany; hypoparathyroidism; osteomalacia and osteoporosis, including the prevention and treatment of osteoporosis associated with hormonal disorders in menopausal women.
Assign inside in the form of drops.
For postnatal specific prophylaxis of rickets in full-term healthy children, the minimum dose is 400-500 ME (1 drop) per day. This dose is used starting from 3-4 weeks of age in the autumn-winter and spring periods during the first two years of life, taking into account the conditions of the child and the risk factors for the development of the disease. Children at risk for rickets are prescribed 1000 ME (2 drops) daily at the same time. In case of prematurity of the first degree, 400-1000 ME (1-2 drops) are used daily, starting from the 10-14th day of life for the first two years (excluding the summer months), with prematurity of the II-III degree - 1000-2000 ME ( 2-4 drops) daily in the first year of life and 500-1000 ME (1-2 drops) in the second year of life (excluding the summer months).
For the treatment of rickets, 2000-5000 ME (4-10 drops) are usually prescribed daily for 30-45 days, after which they switch to a maintenance dose (500 ME) once a day for two years and in the winter in the third year of life ( the dose of 5000 ME is used only for severe bone changes). 3 months after the end of the 1st course, children at risk are given a second course of anti-relapse treatment (2000-5000 ME each) for 3-4 weeks (excluding the summer months).
With proper dosage, the drug is well tolerated.